Swiss drugmaker Novartis’ new gene therapy targeting muscular atrophy, AVXS-101, is cost-effective for hospitals in the range of $4-5 million. Earlier this year, Novartis acquired U.S. gene therapy developer AveXis, which produces the treatment. The cost to patients has not yet been addressed.

Reporting from Reuters here.